Consolidated subsidiary Sinks Healthcare will begin preliminary consultation with PMDA for approval of medical-use hyaluronic acid formulation from April 9, 2026; market launch postponed to March 2028.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"6574","jir_company_name":"Convano Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/6574-20260311-01.pdf","jir_short_summary":"Consolidated subsidiary Sinks Healthcare will begin preliminary consultation with PMDA for approval of medical-use hyaluronic acid formulation from April 9, 2026; market launch postponed to March 2028.","jir_summary":"### Background and Purpose of Preliminary Consultation Start\nSinks Healthcare, a consolidated subsidiary of Convano Corporation, positions the acquisition of PMDA manufacturing and marketing approval for medical-use hyaluronic acid formulation, in collaboration with LG Chem Ltd., as a medium- to long-term growth driver. It was decided to begin preliminary consultation for the approval application from April 9, 2026. This consultation involves discussions with PMDA on key issues such as organizing development concepts, verifying the suitability of non-clinical and clinical data, reviewing clinical trial design policies, and organizing application document preparation policies, aiming to enhance approval certainty and reduce review risks.\n\n### Schedule Changes and Future Outlook\nThe initially planned launch in February 2026 has been postponed to March 2028; however, this reflects strategic refinement to increase approval certainty rather than a mere delay. Since sales of the imported medical-use hyaluronic acid formulation handled by existing import agents have exceeded expectations, the impact on the current fiscal year performance due to the postponement is assessed as minimal. After obtaining approval, the company aims to penetrate the market as a premium formulation leveraging a top-tier domestic quality assurance system. Further timely disclosures will be made as important milestones progress.","jir_financial_highlights":"Incorporated Revenue Amount: JPY 30 million (Cannot be incorporated due to postponement of launch from February 2026 to March 2028)\nPreliminary Consultation Start Date: April 9, 2026 (Scheduled) (Newly established)\nScheduled Launch Date: March 2028 (Scheduled) (Postponed)","jir_category":"","jir_hashtags":"#ConvanoCorporation, #MedicalUseHyaluronicAcidFormulation, #PMDAApproval, #PreliminaryConsultationStart, #BusinessStrategy","jir_key_figures":"Incorporated Revenue Amount: JPY 30 million (changed to not incorporated from previously planned February 2026 launch)\nPreliminary Consultation Start Date: April 9, 2026 (Scheduled)\nScheduled Launch Date: March 2028 (Scheduled)","jir_meta_title":"Convano Corporation Announces Start of PMDA Preliminary Consultation for Medical-Use Hyaluronic Acid Formulation, Launch Postponed to March 2028","jir_meta_description":"Convano Corporation announced that its consolidated subsidiary Sinks Healthcare will start preliminary consultation with PMDA from April 9, 2026, aiming for approval of a medical-use hyaluronic acid formulation, with the market launch postponed to March 2028. The incorporated revenue amount changed from JPY 30 million to not incorporated.","jir_og_title":"Convano Corporation Announces Start of PMDA Preliminary Consultation for Medical-Use Hyaluronic Acid Formulation","jir_og_description":"Announcement on the start of preliminary consultation and postponement of launch for the medical-use hyaluronic acid formulation approval. This is a strategic response aimed at enhancing approval certainty.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17006,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-34172","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n